AbbVie Inc. is a global, diversified research-based biopharmaceutical company with leadership positions across several therapeutic areas, including immunology, oncology, aesthetics, neuroscience, and eye care . The company operates as a single global business segment dedicated to the research, development, manufacturing, commercialization, and sale of innovative medicines and therapies . AbbVie's product portfolio includes blockbuster products such as Humira, Skyrizi, Rinvoq, Imbruvica, Venclexta, Botox, Juvederm, Vraylar, Ubrelvy, and Qulipta, among others .
- Immunology - Develops and markets treatments for autoimmune diseases, with key products including Humira, Skyrizi, and Rinvoq.
- Oncology - Focuses on cancer treatment solutions, featuring products like Imbruvica and Venclexta.
- Neuroscience - Offers therapies for neurological disorders, with significant products such as Vraylar and Botox Therapeutic.
- Aesthetics - Provides cosmetic products and treatments, including Botox and Juvederm.
- Eye Care - Engages in the development and sale of treatments for various eye conditions.
You might also like
| Name | Position | External Roles | Short Bio | |
|---|---|---|---|---|
Robert A. Michael ExecutiveBoard | Chief Executive Officer | None | CEO since July 1, 2024; joined AbbVie in 2013; previously President and COO; key leader in AbbVie’s growth and strategy, including major acquisitions like Allergan. | View Report → |
Azita Saleki-Gerhardt Executive | Executive Vice President, Chief Operations Officer | Board Member at Entegris Inc. | Joined Abbott in 1993; transitioned to AbbVie in 2013; oversees global operations and ESG initiatives; instrumental in achieving carbon emissions targets. | |
David R. Purdue Executive | Senior Vice President, Controller (effective March 1, 2025) | None | Joined Abbott in 2003; transitioned to AbbVie; previously VP, Controller, Commercial Operations; succeeding Kevin K. Buckbee as Controller. | |
Jeffrey R. Stewart Executive | Executive Vice President, Chief Commercial Officer | None | Joined Abbott in 1992; transitioned to AbbVie in 2013; oversees global commercial operations and patient access programs. | |
Kevin K. Buckbee Executive | Senior Vice President, Controller | None | Joined Abbott in 1991; transitioned to AbbVie in 2013; retiring effective March 1, 2025; succeeded by David R. Purdue. | |
Nicholas J. Donoghoe Executive | Executive Vice President, Chief Business and Strategy Officer | None | Joined AbbVie in 2019; previously SVP, R&D Operations; former McKinsey Partner; key leader in portfolio innovation and Allergan integration. | |
Perry C. Siatis Executive | Executive Vice President, General Counsel, and Secretary | None | Joined Abbott in 2005; transitioned to AbbVie in 2013; oversees legal strategy, compliance, and intellectual property. | |
Roopal Thakkar Executive | Executive Vice President, Research & Development, and Chief Scientific Officer | None | Joined Abbott/AbbVie in 2003; leads global R&D organization with over 14,000 team members; oversees pipeline of 90+ drug/device programs. | |
Scott T. Reents Executive | Executive Vice President, Chief Financial Officer | None | CFO since June 2022; joined AbbVie in 2013; previously VP, Tax and Treasury; instrumental in financial strategy and compliance. | |
Timothy J. Richmond Executive | Executive Vice President, Chief Human Resources Officer | None | Joined AbbVie in 2013; oversees HR strategy, including talent acquisition and organizational development. | |
Brett J. Hart Board | Director | President of United Airlines Holdings, Inc. | Director since 2016; brings expertise in risk management, legal strategy, and corporate governance from his leadership roles at United Airlines. | |
Edward J. Rapp Board | Director | Director at Xos, Inc.; Member of University of Missouri College of Business Advisory Board | Director since 2013; former Group President and CFO at Caterpillar; expertise in global operations and sustainability. | |
Frederick H. Waddell Board | Director | Director at IBM | Director since 2013; former CEO of Northern Trust; expertise in financial services and governance. | |
Glenn F. Tilton Board | Director | Director at Phillips 66 | Director since 2013; former lead independent director (2013–2024); extensive experience in governance and finance from leadership roles at United Airlines and Texaco. | |
Jennifer L. Davis Board | Director | CEO, Health Care at Procter & Gamble | Appointed director in October 2023; brings expertise in marketing, corporate strategy, and healthcare operations from her career at P&G. | |
Melody B. Meyer Board | Director | President of Melody Meyer Energy, LLC; Board Member at bp p.l.c. | Director since 2017; extensive experience in operations, sustainability, and energy sector leadership. | |
Rebecca B. Roberts Board | Director | Director at Black Hills Corporation and MSA Safety Incorporated | Director since 2018; former President of Chevron Pipe Line Company; expertise in operations, safety, and regulatory matters. | |
Richard A. Gonzalez Board | Executive Chairman of the Board | None | Founding CEO of AbbVie (2013–2024); transitioned to Executive Chairman on July 1, 2024; led AbbVie’s market cap growth to over $300 billion. | |
Robert J. Alpern Board | Director | Ensign Professor at Yale School of Medicine; Director at Tricida, Inc. | Director since 2013; brings medical and scientific expertise; former Dean of Yale School of Medicine. | |
Roxanne S. Austin Board | Lead Independent Director | President of Melody Meyer Energy, LLC; Board Member at bp p.l.c. | Director since 2013; appointed Lead Independent Director on July 1, 2024; extensive experience in corporate governance and finance. | |
Susan E. Quaggin Board | Director | Chair of Medicine at Northwestern University; Director of Feinberg Cardiovascular and Renal Research Institute | Appointed director in October 2023; brings medical and scientific expertise; former President of the American Society of Nephrology. | |
Thomas C. Freyman Board | Director | None | Director since 2020; former EVP, Finance and Administration at Abbott; expertise in finance and risk oversight. | |
William H.L. Burnside Board | Director | None | Director since 2013; retired Senior VP at Boston Consulting Group; expertise in corporate finance and strategic advisory. |
-
Given the ongoing economic challenges in China that have significantly impacted Juvederm's performance, particularly within the Aesthetics segment, what specific strategies does AbbVie have to navigate these headwinds and stimulate growth in this critical market?
-
With the recent $100 million downward adjustment in VRAYLAR's full-year sales guidance due to channel mix pressures and negative pricing impact, can you elaborate on the factors leading to this shift and how you plan to mitigate similar issues moving forward?
-
In the competitive immunology space, your head-to-head trial of SKYRIZI against ENTYVIO aims for potential superiority in endoscopic improvement for ulcerative colitis patients; what gives you confidence in achieving this outcome, and what are the implications if the trial does not meet its superiority endpoints?
-
As SKYRIZI and RINVOQ continue to drive significant growth, what challenges do you foresee in maintaining their momentum across existing indications, and how do you plan to address potential competition from new market entrants and evolving treatment paradigms?
-
With the integration of Cerevel Therapeutics and the upcoming pivotal study readouts for emraclidine in schizophrenia, how is AbbVie preparing to compete against existing therapies, especially considering recent approvals with safety considerations like hepatic monitoring, and what are your expectations regarding emraclidine's safety and efficacy profile?
Research analysts who have asked questions during AbbVie earnings calls.
Mohit Bansal
Wells Fargo & Company
4 questions for ABBV
Steve Scala
Cowen
4 questions for ABBV
Terence Flynn
Morgan Stanley
4 questions for ABBV
Vamil Divan
Guggenheim Securities
4 questions for ABBV
Carter L. Gould
Barclays
3 questions for ABBV
Christopher Schott
JPMorgan Chase & Co.
3 questions for ABBV
David Risinger
Leerink Partners
3 questions for ABBV
Geoffrey Meacham
Citi
3 questions for ABBV
Trung Huynh
UBS Group AG
3 questions for ABBV
Chris Shibutani
Goldman Sachs Group, Inc.
2 questions for ABBV
James Shin
Analyst
2 questions for ABBV
Timothy Anderson
BofA Securities
2 questions for ABBV
Alexandria Hammond
Wolfe Research
1 question for ABBV
Asad Haider
Goldman Sachs
1 question for ABBV
Chris Schott
JPMorgan Chase & Co.
1 question for ABBV
Christopher Raymond
Piper Sandler
1 question for ABBV
Courtney Breen
AllianceBernstein
1 question for ABBV
Evan Seigerman
BMO Capital Markets
1 question for ABBV
Gary Nachman
Raymond James
1 question for ABBV
Jon Win
UBS
1 question for ABBV
Luisa Hector
Berenberg
1 question for ABBV
Tim Anderson
Bank of America
1 question for ABBV
| Customer | Relationship | Segment | Details |
|---|---|---|---|
McKesson Corporation | Wholesale distributor | US Pharmaceuticals | Accounts for <39% of 2024 US gross revenues ; collectively with the other two wholesalers, they represent substantially all US pharma sales. |
Cardinal Health, Inc. | Wholesale distributor | US Pharmaceuticals | Accounts for <39% of 2024 US gross revenues ; collectively with the other two wholesalers, they represent substantially all US pharma sales. |
Cencora, Inc. | Wholesale distributor | US Pharmaceuticals | Accounts for <39% of 2024 US gross revenues ; collectively with the other two wholesalers, they represent substantially all US pharma sales. |
Notable M&A activity and strategic investments in the past 3 years.
| Company | Year | Details |
|---|---|---|
Nimble Therapeutics | 2025 | AbbVie completed its acquisition of Nimble Therapeutics in January 2025 by paying $200 million upfront with potential milestone payments up to $130 million, aiming to enhance its immunology R&D pipeline with an investigational oral peptide IL23R inhibitor and a proprietary peptide synthesis platform. |
ImmunoGen, Inc. | 2024 | AbbVie acquired ImmunoGen, Inc. in February 2024 for approximately $9.8 billion in total value, strengthening its oncology portfolio with antibody-drug conjugate (ADC) technology including the first-in-class product ELAHERE for platinum-resistant ovarian cancer. |
Cerevel Therapeutics Holdings, Inc. | 2024 | Completed on August 1, 2024, the acquisition of Cerevel Therapeutics involved a cash payment of $45.00 per share, totaling about $8.7 billion, and strategically expanded AbbVie's neuroscience portfolio while integrating a licensing agreement with Pfizer that could trigger additional milestone payments up to $1.6 billion. |
Syndesi Therapeutics SA | 2022 | Acquired in February 2022 for an upfront payment of $130 million with contingent future payments up to $870 million, this deal provided AbbVie access to Syndesi's SV2A modulator portfolio, including the lead molecule SDI-118 in Phase 1b studies aimed at enhancing synaptic efficiency. |
DJS Antibodies Ltd | 2022 | In 2022, AbbVie acquired DJS Antibodies Ltd for approximately $255 million upfront plus up to $95 million in future milestone payments, obtaining the DJS-002 LPAR1 antagonist antibody program and the HEPTAD platform for novel antibody discovery targeting fibrotic diseases. |
Recent press releases and 8-K filings for ABBV.
- Enveric Biosciences has engaged Fish & Richardson P.C. to defend its U.S. Patent No. 12,138,276, which includes claims potentially relevant to Bretisilocin (GM-2505) in clinical trials, recently acquired by AbbVie for up to $1.2 billion on August 25, 2025.
- The ’276 patent family comprises one issued U.S. patent, additional issued and pending U.S. applications, plus international filings in Australia, Canada, China, Europe, Japan, Mexico, and South Korea, but does not cover Enveric’s proprietary EB-003 program.
- Enveric’s broader IP estate includes 26 issued U.S. patents and 60 pending national and international applications across five programs.
- Through out-licensing agreements, Enveric is eligible to receive up to $205 million in upfront, development, and sales milestones, plus royalties on future sales.
- The FDA has expanded the approved use of Rinvoq to treat adults with moderately to severely active ulcerative colitis and Crohn’s disease after at least one systemic therapy when TNF blockers are clinically inadvisable, up from prior approval only for TNF-intolerant or unresponsive patients.
- AbbVie holds a $411 billion market capitalization and focuses on immunology and oncology products such as Humira, Skyrizi, and Rinvoq.
- Despite this regulatory win, AbbVie reported $58.33 billion in revenue, a three-year growth rate of 0.2%, a net margin of 6.45%, a current ratio of 0.74, and an Altman Z-Score of 2.14, signaling potential financial stress.
- Insider selling activity totaled 55,665 shares over the past three months, which may raise governance concerns.
- The U.S. FDA approved an updated indication for RINVOQ® (upadacitinib) to treat adults with moderately to severely active ulcerative colitis and Crohn’s disease after at least one systemic therapy when TNF blockers are clinically inadvisable.
- The revised label allows the use of RINVOQ prior to TNF-blocking agents in patients for whom TNF blockers are deemed clinically inadvisable, expanding therapeutic options.
- Key safety considerations include risks of serious infections, increased cardiovascular events in patients aged 50+ with risk factors, cancer, and blood clots.
- AbbVie will support patient access through a co-pay assistance card and its myAbbVieAssist program for uninsured or underinsured patients.
- AbbVie will unveil data from telisotuzumab adizutecan (Temab-A) in combination with bevacizumab in advanced colorectal cancer, achieving a 26.7% ORR versus 0% with standard of care (n=30).
- Temab-A monotherapy in MET-amplified solid tumors delivered a 46% ORR overall, including 69% in NSCLC and 71% in gastroesophageal adenocarcinoma (n=100).
- In pancreatic ductal adenocarcinoma post-first-line therapy, Temab-A showed a 24% overall ORR and 40% ORR in patients previously treated with gemcitabine-nab-paclitaxel (n=42).
- AbbVie's SEZ6-targeting ADC, ABBV-706, demonstrated potential to replace platinum-based first-line therapy in small cell lung cancer based on paired PFS analysis and ctDNA clearance correlations (n=80).
- The Phase 2 ELATE trial of onabotulinumtoxinA (BOTOX®) met its primary endpoint, with a significant reduction in Tremor Disability Scale-Revised total unilateral score at week 18 (−2.61 vs. −1.61; p=0.029).
- All six secondary endpoints were also met, supporting the efficacy of onabotulinumtoxinA in upper limb essential tremor.
- The safety profile aligned with known BOTOX® data; muscular weakness was the most common adverse event (24.5% vs. 2.3% for placebo).
- Full results will be presented at the International Congress of Parkinson’s Disease and Movement Disorders on October 8, 2025.
- AbbVie expects $2.7 billion in acquired IPR&D and milestones expense for Q3 2025, reducing GAAP and adjusted diluted EPS by $1.50 per share.
- Full-year 2025 adjusted diluted EPS guidance is now $10.38–$10.58, inclusive of the Q3 expense.
- Third quarter 2025 adjusted diluted EPS guidance, including the acquired IPR&D and milestones expense, is $1.74–$1.78.
- The company does not forecast IPR&D and milestones expense beyond Q3 2025 due to timing uncertainty.
- Allergan Aesthetics, an AbbVie company, was named a Natrelle® supplier by Vizient, connecting the brand to a network representing more than half of U.S. healthcare organizations.
- Vizient clients gain enhanced access to Natrelle’s 300+ implant options, competitive pricing, simplified procurement, and direct sales and technical support.
- Natrelle is the #1 selected breast implant by plastic surgeons, per an August 2024 survey of 478 clinicians.
- $70 million expansion at AbbVie Bioresearch Center in Worcester, Mass., to boost domestic biologics manufacturing for immunology and oncology.
- Part of AbbVie’s $10 billion U.S. capital commitment, including a three-story building with labs, warehouse, and offices.
- Aims to meet global demand, expedite transfer of select oncology products from Europe, and enhance R&D capacity.
- Expansion will create new jobs at the site and further support over 6,000 U.S. manufacturing jobs across 11 sites.
- AbbVie has submitted a Biologics License Application (BLA) to the U.S. FDA for Pivekimab sunirine (PVEK) to treat Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), based on data from the Phase 1/2 CADENZA trial.
- PVEK is a CD123-targeting antibody-drug conjugate (ADC) and represents AbbVie’s first ADC in blood cancers, targeting a rare and aggressive malignancy with limited treatment options.
- The CADENZA trial evaluated safety, tolerability, pharmacokinetics, immunogenicity and antileukemia activity, and established the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) for PVEK monotherapy.
- PVEK is also being studied in combination with Vidaza® (azacitidine) and Venclexta® (venetoclax) in acute myeloid leukemia (AML) and has held a Breakthrough Therapy designation in relapsed/refractory BPDCN since October 2020.
- US$10 million milestone payment received by Nxera, marking the second R&D milestone under their 2022 GPCR-focused neurological disease collaboration (first milestone achieved June 2024).
- Collaboration offers up to US$40 million in near-term research milestones and up to US$1.2 billion in development/commercial milestones plus tiered royalties on global sales.
- The payment will be recognized in Q3 2025.
- Collaboration leverages Nxera’s NxWave™ discovery platform to identify and validate novel hit molecules against neurological targets.